Dickstein, Daniel P.
Axelson, David
Weissman, Alexandra B.
Yen, Shirley
Hunt, Jeffrey I.
Goldstein, Benjamin I.
Goldstein, Tina R.
Liao, Fangzi
Gill, Mary Kay
Hower, Heather
Frazier, Thomas W.
Diler, Rasim S.
Youngstrom, Eric A.
Fristad, Mary A.
Arnold, L. Eugene
Findling, Robert L.
Horwitz, Sarah M.
Kowatch, Robert A.
Ryan, Neal D.
Strober, Michael
Birmaher, Boris
Keller, Martin B.
Funding for this research was provided by:
National Institute of Mental Health (K22MH074945)
National Institute of Mental Health (R01MH059929, R01MH059929, R01MH059929, R01MH073953, R01MH073967, R01MH073801, R01MH073816)
Article History
Received: 3 March 2015
Accepted: 1 September 2015
First Online: 5 October 2015
Compliance with ethical standards
:
: Drs. Dickstein, Axelson, Diler, T. Goldstein, Ryan, Liao, Yen, Horwitz, and Kowatch, as well as Ms. Mary Kay Gill, Ms. Heather Hower, and Ms. Alexandra Weissman report no biomedical financial interests or potential conflicts of interest. Dr. Birmaher has received royalties from Random House, Inc., and Lippincott Williams & Wilkins. Dr. Frazier has received federal funding or research support from, acted as a consultant to, received travel support from, and/or received a speaker’s honorarium from the Simons Foundation, Ingalls Foundation, Forest Laboratories, Ecoeos, IntegraGen, Kugona LLC, Shire Development, Bristol-Myers Squibb, National Institutes of Health, and the Brain and Behavior Research Foundation. Dr. Fristad has received royalties from Guilford Press, American Psychiatric Press, and CFPSI Press. Dr. B. Goldstein is a consultant for BMS, has received research support from Pfizer, and has received speaker’s honoraria from Purdue Pharma. Dr. Hunt is a senior editor of Brown Child and Adolescent psychopharmacology update, and receives honoraria from Wiley Publishers. Dr. Keller receives research support from Pfizer, and has received honoraria from Medtronic. Dr. Strober receives support from the Resnick Endowed Chair in Eating Disorders. Dr. Youngstrom has consulted with Lundbeck and Otsuka. Dr. Arnold has received research funding from Curemark, Forest, Lilly, Neuropharm, Novartis, Noven, and Shire (as well as NIH and Autism Speaks) and has consulted with or been on advisory boards for Gowlings, Neuropharm, Novartis, Noven, Organon, Otsuka, Pfizer, Roche, Seaside Therapeutics, Sigma Tau, Shire, and Tris Pharma and received travel support from Noven. Dr. Findling receives or has received research support, acted as a consultant and/or served on a speaker’s bureau for Alexza Pharmaceuticals, American Academy of Child & Adolescent Psychiatry, American Physician Institute, American Psychiatric Press, AstraZeneca, Bracket, Bristol-Myers Squibb, Clinsys, Cognition Group, Coronado Biosciences, Dana Foundation, Forest, GlaxoSmithKline, Guilford Press, Johns Hopkins University Press, Johnson & Johnson, KemPharm, Lilly, Lundbeck, Merck, NIH, Novartis, Noven, Otsuka, Oxford University Press, Pfizer, Physicians Postgraduate Press, Rhodes Pharmaceuticals, Roche, Sage, Seaside Pharmaceuticals, Shire, Stanley Medical Research Institute, Sunovion, Supernus Pharmaceuticals, Transcept Pharmaceuticals, Validus, and WebMD.
: This study was reviewed and approved by the institutional review boards of all sites prior to the enrollment of any participant. This includes the IRBs of: (1) the Course and Outcome of Bipolar Youth (COBY) study (sites: University of Pittsburgh Medical Center, Brown University, and the University of California Los Angeles); (2) the Longitudinal Assessment of Manic Symptoms (LAMS; sites: University of Pittsburgh, Case-Western Reserve University, University of Cincinnati), and (3) Dr. Dickstein’s Pediatric Mood, Imaging, and NeuroDevelopment (PediMIND) studies. All participants gave their informed consent prior to inclusion in the study.